![First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S155608642103207X-gr3ab.jpg)
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
![First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open](https://www.esmoopen.com/cms/asset/6074a8cd-117e-4f46-bd31-b0fdb2165760/gr1cd.jpg)
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open
![New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer](https://dailynews.ascopubs.org/do/10.1200/ADN.22.201166/full/brahmer_julie_r_570px.jpg)
New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer
![Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/clin-onc-2020/lung/text-module-thumbs/asco_2020_lung_cancer_ea_thumb-13.png?rev=54193d3481ca44c5b544c15a06907dcc)
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
![🇨🇦🏥🥷 Twitterren: "But not to worry: CHECKMATE-227 is hear to save the day! WOW look at those sweet PFS curves... and independent of PD-L1! Who needed that test anyway when I can 🇨🇦🏥🥷 Twitterren: "But not to worry: CHECKMATE-227 is hear to save the day! WOW look at those sweet PFS curves... and independent of PD-L1! Who needed that test anyway when I can](https://pbs.twimg.com/media/DpCUacFVsAAQjOF.jpg)
🇨🇦🏥🥷 Twitterren: "But not to worry: CHECKMATE-227 is hear to save the day! WOW look at those sweet PFS curves... and independent of PD-L1! Who needed that test anyway when I can
![Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer](https://www.frontiersin.org/files/Articles/760686/fonc-11-760686-HTML/image_m/fonc-11-760686-g001.jpg)
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
![Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2021/clinical-oncology-2021/lung/asco-2021-lung-cancer-ea/asco_2021_lung_cancer_ea_thumb-55.png?rev=dbb033e6b6d54f39a32be14625ad1446)
Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options
![First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S155608642103207X-gr1.jpg)
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
![First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S155608642103207X-gr2cd.jpg)
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
![CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC) CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)](https://www.ilcn.org/wp-content/uploads/2021/12/506.jpg)
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC - ILCN.org (ILCN/WCLC)
![ASCO 2022: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227. ASCO 2022: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1655144106208038020362a77eaac47cc.jpg)
ASCO 2022: Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
![Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram](https://www.researchgate.net/publication/356901139/figure/fig1/AS:1099097553543181@1639056685982/Comparisons-between-the-CheckMate-227-trial-and-simulation-overall-survival-for.png)
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
![JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point) JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)](https://pbs.twimg.com/media/FGBgkqBXIAYRI64.jpg:large)
JTO & JTO CRR on Twitter: "In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival versus chemotherapy in patients w/tumor programmed death-ligand 1 greater than or equal to 1% (primary end point)
Kaplan-Meier curves after matching adjustment for (A) overall survival... | Download Scientific Diagram
![Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2021/clinical-oncology-2021/lung/asco-2021-lung-cancer-ea/asco_2021_lung_cancer_ea_thumb-58.png?rev=572b1989ece249a384515d4cf9e01fcf)
Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options
![Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology](https://www.thelancet.com/cms/attachment/755a9194-decd-44b1-8d75-55329dccf733/gr1_lrg.jpg)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
![Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/clin-onc-2020/lung/text-module-thumbs/asco_2020_lung_cancer_ea_thumb-12.png?rev=8d53e5168d414d1e91b96b716a78745b)